Bio-Rad Laboratories (NYSE:BIO.B) Hits New 12-Month High – Here’s What Happened

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $379.50 and last traded at $379.50, with a volume of 204 shares trading hands. The stock had previously closed at $365.08.

Bio-Rad Laboratories Price Performance

The firm has a market cap of $10.15 billion, a price-to-earnings ratio of 46.00 and a beta of 0.96. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $363.13 and its 200-day moving average price is $309.70.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (NYSE: BIO.B) develops, manufactures and markets products and systems used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers with laboratory instruments, reagents, consumables, software and related services.

Its life science portfolio includes technologies for genomics, digital PCR, protein analysis, chromatography, electrophoresis, cell biology and imaging. Bio-Rad’s clinical diagnostics business provides systems and reagents used in areas such as diabetes monitoring, blood typing, quality control, infectious disease testing and autoimmune diagnostics.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia-Pacific and other international markets.